Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Ian Carroll, PhD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01072916
First received: February 18, 2010
Last updated: April 3, 2014
Last verified: April 2014

February 18, 2010
April 3, 2014
February 2009
December 2015   (final data collection date for primary outcome measure)
fecal serine protease activity [ Time Frame: protease activity determined at at recruitment ] [ Designated as safety issue: No ]
we will use an elisa-based method to measure the activity of serine proteases in fecal samples from IBS and HC subjects
Not Provided
Complete list of historical versions of study NCT01072916 on ClinicalTrials.gov Archive Site
intestinal permeability [ Time Frame: 6hrs following recruitment ] [ Designated as safety issue: No ]
We will analyze sugar concentrations in urine to determine the level of intestinal permeability.
Not Provided
Not Provided
Not Provided
 
Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)
The Role of Serine-Proteases in Gastrointestinal Function and Irritable Bowel Syndrome

The proposed pilot project for this seed grant focuses on the role of intestinal serine-proteases in the pathogenesis of diarrhea-predominant IBS (D-IBS). In this study we will further assess serine-protease activity in patients with D-IBS and also explore a possible mechanism by which these proteases can lead to alterations in intestinal physiology and symptoms in these patients.

The general hypotheses for the proposed research are that (A) the levels of fecal serine-protease in patients with D-IBS are abnormally increased (B) this abnormal serine-protease activity leads to/is associated with an abnormal increase in intestinal permeability and therefore enables (C) chronic stimulation and activation of the mucosal immune system in these patients. In addition, it is aim to determine whither periodontal inflammation is associated with intestinal permeability and serine protease activity.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Urine and Stool.

Non-Probability Sample

Men and women of any race or ethnicity at least 18 years or older who have Diarrhea predominant Irritable Bowel Syndrome (D-IBS, n = 30) and healthy controls (n = 30).

Colon, Irritable
Not Provided
  • IBS
    Subjects with IBS-D
  • Healthy
    Healthy Subjects

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any sex, race, or ethnicity.
  • At least 18 years of age (no upper age limit).
  • D-IBS patients must meet Rome III criteria for IBS and must have been evaluated by a physician to exclude other diseases that could explain the symptoms. For the latter, patients self statement is acceptable (no official document is required).
  • Participation in Dr. Whitehead's 'heterogeneity of IBS' and/or Dr. Ringel's 'intestinal inflammation in patients with D-IBS' research study.

Exclusion Criteria:

  • Healthy controls must have no significant or recurring gastrointestinal symptoms.
  • Patients and healthy controls should not have a serious, unstable medical condition.
  • Patients and healthy controls must have had no gastrointestinal tract surgery other than appendectomy or cholecystectomy.
  • Patients and healthy controls must not be pregnant (by self-report). Pregnant women will not be allowed to participate as pregnancy can affect gastrointestinal symptoms.
  • Patients and healthy controls must not have a history of inflammatory bowel disease, celiac disease, or other diagnosis that could explain chronic or recurring bowel symptoms in IBS patients or controls.
  • Patients and healthy controls should have no history of lactose malabsorption (by self-report).
  • Patients and healthy controls should have no history of clinical symptoms of acute infections during the last 8 weeks prior to enrolment in the study.
  • Patients and healthy controls should have no history of anti-inflammatory agents including aspirin, non-aspirin, non-steroid anti-inflammatory (NSAID) or steroids in the last four weeks prior to study enrollment.
  • Patients should not intentionally consume probiotics or undergo antibiotic treatment during the last 4 weeks prior to enrolment in the study. If the subject consumed any of these medications, a washout period of 4 weeks will be required).
  • Patients must have no history of fainting or light headedness during periods of fasting.
  • Patients must not have diabetes mellitus, or any similar conditions, that would cause an adverse reaction to the sugar drink.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01072916
08-1149, R24DK067674
No
Ian Carroll, PhD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Ian M Carroll, PhD UNC Chapel Hill Department of Gastroenterology and Hepatology
University of North Carolina, Chapel Hill
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP